On the morning of the 10th, Professor Jin-Hyoung Kang of Medical Oncology at the Catholic University of Korea Seoul St. Mary's Hospital, said, "LASER 301,' the global Phase III clinical trial on Leclaza (lazertinib), is the only study that demonstrated the drug's efficacy as a first-line treatment for EGFR mutation-positive non-small cell lung cancer patients in Korea,” during a press conference held to celebrate Leclaza's approval as first-line treatment at Seoul Plaza Hotel.

Leclaza is Korea's 31st homegrown novel drug that was approved for the treatment of NSCLC in January 2021. At the time of its approval, the drug was approved as a second-line treatment for patients with locally advanced